| Similar Articles |
|---|
 |
The Motley Fool
November 16, 2007
Billy Fisher |
Megagrowth at Meridian Bioscience The biotech, a consistent performer for five years now, produces another quarter of record revenue and earnings. Investors, take note.   |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
October 26, 2007
Billy Fisher |
A Quarter to Boast About at Bristol Bristol-Myers announces a 22% rise in third-quarter revenue as Plavix sales continue to rise. Investors, take note. |
The Motley Fool
January 3, 2007
Brian Lawler |
Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note. |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
The Motley Fool
May 30, 2008
Brian Lawler |
Bristol-Myers' Cheap Pipeline Bet Bristol-Myers announces that it is acquiring development-stage drugmaker Kosan Biosciences for a net price of $190 million in cash. |
The Motley Fool
April 28, 2008
Brian Lawler |
Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results. |
The Motley Fool
August 29, 2008
Brian Lawler |
Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity? |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
March 29, 2007
Brian Lawler |
Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note. |
The Motley Fool
September 11, 2007
Brian Lawler |
Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans. |
The Motley Fool
July 10, 2007
Brian Orelli |
Sometimes, the Same Is Good Enough Bristol-Myers Squibb's new drug doesn't work better, but it's easier to take. Investors, take note. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
November 1, 2004
Brian Gorman |
Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes. |
The Motley Fool
October 8, 2007
Billy Fisher |
Wheeling and Dealing at Wyeth A busy day at Wyeth. The company plans to submit a New Drug Application to the FDA, and acquires biopharmaceutical firm Haptogen. |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
November 24, 2008
Brian Orelli |
Bristol Rolls Snake Eyes in Europe European officials reject Bristol-Myers Squibb's breast cancer treatment, Ixempra. |
The Motley Fool
April 13, 2007
Brian Lawler |
Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note. |
The Motley Fool
December 26, 2007
Brian Lawler |
Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
The Motley Fool
April 29, 2004
Brian Gorman |
Merck, Bristol-Myers Team Up Their agreement to commercialize a diabetes drug reflects intense sales competition in the industry. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year. |
The Motley Fool
June 29, 2007
Brian Lawler |
Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
December 18, 2009
Brian Orelli |
Buy a Company, Get the Plant for Free Earlier this year, Merck company bought a pipeline of follow-on biologics (and a manufacturing plant to make them in) from Insmed. Now it's back for more with an acquisition of Avecia Biologics. |
The Motley Fool
March 5, 2010
Brian Orelli |
How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool
December 15, 2009
Brian Orelli |
It's Nice to Have Friends With Cash Array hits up Amgen for some much-needed cash. |
The Motley Fool
August 23, 2005
W.D. Crotty |
A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look? |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
September 17, 2008
Brian Orelli |
IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
September 10, 2008
Brian Orelli |
Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies. |
The Motley Fool
June 25, 2007
Brian Orelli |
Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Bristol-Myers: Hang in There Generics are wreaking havoc on growth, but patient investors can pin hopes on drugs now in the pipeline. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
The Motley Fool
November 9, 2006
Karl Thiel |
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
March 30, 2005
Stephen D. Simpson |
Clinical Trials Cost Biotechs More The failure of edifoligide means little to Bristol-Myers, but a great deal to Corgentech. In the grand scheme of things, there's not much new here -- the large, well-stocked pharmaceutical goes on its way, and the biotech stock gets pummeled. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
March 3, 2009
Brian Orelli |
Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think. |
The Motley Fool
April 2, 2008
Brian Lawler |
Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders. |
The Motley Fool
January 14, 2008
Brian Lawler |
Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
The Motley Fool
July 25, 2008
Brian Lawler |
Glaxo Changes Course Will a shift in strategy turn the drugmaker around? |
